Navigation Links
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Date:9/2/2008

ere 1.406 and 1.199L for ACCLAIM/COPD I and ACCLAIM/COPD II, respectively. Patients were randomized to receive aclidinium bromide (200 micrograms once daily) or placebo over a one-year treatment period.

The primary endpoints for ACCLAIM/COPD I and II were bronchodilation at the end of the dosing interval, assessed as trough FEV1 (measured at 23-24h post-dose). For both trials, the primary endpoint was measured at week 12 and week 28 to fulfill FDA and European requirements, respectively.

Aclidinium bromide and placebo were administered to patients using the Genuair(R)(1) device, a multi-dose dry powder inhaler which operates by a 'one press and inhale' technique.

Overall, safety and tolerability were comparable between aclidinium and placebo in terms of percentage of patients with Serious Adverse Events (aclidinium: 9.1%, placebo 10.7%), Fatal Adverse Events (aclidinium: 1.1%, placebo: 1.7%), or with Adverse Events leading to treatment discontinuation (aclidinium: 4.0%, placebo: 5.7%). The most frequently reported adverse events across both studies were nasopharyngitis (aclidinium: 14.5%, placebo: 12.9%) and headache (aclidinium: 12.7%, placebo: 12.6%). Potential anticholinergic adverse events were observed in a similarly low percentage of patients, (e.g. dry mouth - aclidinium: 0.7%, placebo: 1.2%).

"Almirall remains committed to continue the efforts to provide treatment options for COPD patients with aclidinium bromide", commented Jorge Gallardo, Chairman and Chief Executive Officer of Almirall.

About COPD

The World Health Organisation (WHO) has described COPD as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.

The most
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Inari Medical, Inc. announced ... B venture capital financing. The financing was led by ... Versant Ventures and US Venture Partners.  The round also ... "We are very pleased to complete this financing ... Bill Hoffman , who joined in February 2015 ...
(Date:6/30/2015)... , June 30, 2015  Avanir Pharmaceuticals, Inc. ... study showing that treatment with NUEDEXTA ® ... symptoms of pseudobulbar affect (PBA) in patients with ... a distressing condition characterized by sudden and uncontrollable ... neurologic diseases or brain injury. PRISM II is ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ – ... ARYC) had an agreement to supply custom Arrayit blood ... private human DNA vault on earth. Vivos offers an ... provide virtually every man, woman and child on Earth, ... store their DNA. Arrayit blood cards allow the rapid ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7Small Cap IR - Empowering the Age of Genetic Enlightenment 2
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) today announced ... ( www.safcglobal.com ), is introducing a novel CHOZN® GS-/- ... line. Designed for use in the production of biopharmaceuticals, ... commercially available glutamine synthetase (GS) knockout CHO cell line ...
...  The Eli Lilly and Company Foundation has committed US $30 ... in its fight against multidrug-resistant tuberculosis – a disease that ... each year. The announcement was made ahead of the opening ... Lille, France, later this week. Eli Lilly ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 2Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 3Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 4Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership 5
(Date:6/30/2015)... , ... June 30, 2015 , ... ... call and communications software, Notify™, for the senior care sector. As an innovator ... helping senior housing facilities to become more efficient and offer residents better care. ...
(Date:6/30/2015)... ... June 30, 2015 , ... Nuretix ... with Knockout Zone Miami (KO Zone), a state-of-the-art training facility ... CrossFit Coach, Diego de Vera. The partnership will provide KO Zone clients and ...
(Date:6/30/2015)... ... ... The campaign aims to make digestive wellness a more conversational topic, educating on the ... Americans face and inspiring readers to be more proactive by providing them the tools ... “Digestive Wellness” is distributed within USA Today in Los Angeles, New York, Chicago, Miami ...
(Date:6/30/2015)... Soledad, CA (PRWEB) , ... June 30, 2015 , ... ... off the florets once in the kitchen, and discard the stalks before cooking. Throwing ... parts actually can be eaten and are quite delicious. It just takes a little ...
(Date:6/30/2015)... ... 2015 , ... When it comes to volunteering abroad, not many people end ... be too high. However, there are affordable programs to be had such as those ... cost. One such volunteer named Uzma Aishah, a student at the International Medical University ...
Breaking Medicine News(10 mins):Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 2Health News:Eldermark Leap-Frogs other Nurse Call and Communication Systems with Notify 3Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3Health News:Mediaplanet’s “Digestive Wellness” Campaign Urges You To Listen to What Your Stomach Is Telling You and Talk About It 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 2Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 3Health News:Whole Vegetable Cooking for Home Cooks: Josie's Organics Encourages Using All Parts of Vegetables – from Root to Stalk – Every Day 4Health News:Volunteers Transform Themselves and Their Resumes with Medical Volunteer Placements Abroad 2Health News:Volunteers Transform Themselves and Their Resumes with Medical Volunteer Placements Abroad 3
... Davis team of cardiovascular specialists has demonstrated the effectiveness of ... to repair aortas that are torn as the result of ... Association for Thoracic Surgery Aortic Symposium 2010, which takes place ... looking for ways to reduce the impact of surgical treatment ...
... the dawn of a new age in genomics, researcher says ... a Stanford University professor of bioengineering, now has a very ... was the focus of the first completely mapped genome of ... The scan was conducted by a team of Stanford researchers ...
... transplant recipients are known to have a higher risk of ... to take immunosuppressive drugs to prevent organ rejection. Results published ... medication appears to increase this cancer risk. Evaluating data ... trends among 481 patients over 20 years - providing the ...
... Can medicine, science and faith ... proper evidences that reveal the existence of our souls, Heaven and God? If so, where ... to Heaven and returned to tell us about it in this day and age? , ... (PRWEB) April 30, 2010 -- Many profound questions ...
... say the measure makes the wrong changes, poll finds ... after President Barack Obama signed the historic health-reform bill ... many people still unsure how it will affect them, ... opponents of the reform package are roughly equally divided, ...
... SUPERNANNY New York Open Casting Call for ... Saturday May 15th from 2 to 6PM. Lucie B,s Jump N Fun is the First and ... Sip on Seltzer, Have Fun...and Maybe make the cut for SUPERNANNY. , ... Baldwin, New York (PRWEB) April 30, 2010 -- Lucie B,s Jump N Fun has ...
Cached Medicine News:Health News:Research team documents benefits of endovascular stent repair for traumatic aortic injury 2Health News:Genome Scan Gives Man Insight Into Future Health Risks 2Health News:Genome Scan Gives Man Insight Into Future Health Risks 3Health News:Cancer risk for kidney transplant 2Health News:Secrets to Life, the Shroud of Turin, and Heaven's Mysteries Revealed 2Health News:Secrets to Life, the Shroud of Turin, and Heaven's Mysteries Revealed 3Health News:Americans Still Split Over New Health Reform Law 2Health News:Americans Still Split Over New Health Reform Law 3Health News:Americans Still Split Over New Health Reform Law 4Health News:Supernanny New York Casting Call @ Lucie B's Jump N Fun- NY's 1st Jump Rope Gym For Kids in Baldwin 2
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Short 19 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
Double ended dilator probes with gentle curve. Stainless steel. Round knurled handle with polished finish. Overall length: 5.3 inches....
Medicine Products: